Global Cancer Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts - Reportlinker Review
NEW YORK, Oct. 22, 2015 /PRNewswire/ -- The Global Cancer Diagnostics Partnering 2010-2015 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in cancer diagnostics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer diagnostics partnering contract documents
Top cancer diagnostics deals by value
The Global Cancer Diagnostics Partnering 2010-2015 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why companies enter cancer diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest cancer diagnostics agreements announced in the healthcare sectors covering the following diagnostics types.
Diagnostics
Companion
Imaging
CT
Endoscope
Molecular and nuclear
PET
SPECT
MRI
Ultrasound
X ray
Angiography
Fluoroscopy
Mammography
In vitro diagnostics
Molecular diagnostics
Prognostics
Theranostics
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual cancer diagnostics deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report takes readers through the comprehensive cancer diagnostics deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cancer diagnostics partnering deals.
The report presents average financial deal terms values for cancer diagnostics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The middle section of the report explores the leaders in the cancer diagnostics partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.
One of the key highlights of the report is that over 1,000 online deals records of actual cancer diagnostics deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.
Report scope
Global Cancer Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.
Global Cancer Diagnostics Partnering 2010-2015 includes:
Trends in cancer diagnostics dealmaking in the biopharma industry since 2010
Analysis of cancer diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Access to over 1,000 cancer diagnostics deal records
The leading cancer diagnostics deals by value since 2010
Includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances since 2010
In Global Cancer Diagnostics Partnering 2010-2015, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
DIagnostics type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Cancer Diagnostics Agreements report provides comprehensive access to available deals and contract documents for over 1,000 cancer diagnostics deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?Global Cancer Diagnostics Partnering 2010-2015 provides the reader with the following key benefits:
In-depth understanding of cancer diagnostics deal trends since 2010
Access to headline, upfront, milestone and royalty data
Access to the structure of cancer diagnostics agreements with numerous real life case studies
Comprehensive access to over 1,000 actual cancer diagnostics deals entered into by the world's biopharma companies, together with real world clause examples
Full listing of cancer diagnostics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
Identify leading cancer diagnostics deals by value since 2009
Identify the most active cancer diagnostics dealmakers since 2010
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Read the full report: http://www.reportlinker.com/p03095641-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker reviews, finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article